Debra Yu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

LianBio Announces President and Chief Strategy Officer

SHANGHAI, China and PRINCETON, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative.

Katherine smithDebra yuJosh xuYizhe wangElizabeth andersonExchange commissionVp communicationsChief strategy officerChief executive officerAnnual reportNasdaq lian

LianBio Announces President and Chief Strategy Officer Departure

LianBio Announces President and Chief Strategy Officer Departure
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Katherine smithDebra yuJosh xuYizhe wangElizabeth andersonExchange commissionVp communicationsChief strategy officerChief executive officerAnnual reportInvestor relationseEvoke canalee

MeiraGTx Appoints Debra Yu, MD to Board of Directors

MeiraGTx Appoints Debra Yu, MD to Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jason bracoDebra yuPrinceton universityLabrador advisorsHarvard medical schoolMeiragtx holdingsLifesci communicationsWorldwide business developmentWall streetChief strategy officerChief businessSan francisco bayHarvard medicalAlexandria forbes

MeiraGTx Appoints Debra Yu, MD to Board of Directors

City ofUnited kingdomJason bracoDebra yuPrinceton universityLabrador advisorsHarvard medical schoolPh dlifesci communicationsMeiragtx holdingsWorldwide business developmentChief strategy officerChief businessSan francisco bayHarvard medicalAlexandria forbes

NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer

Search jobs 11-May-2021 NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets LianBio to collaborate in the development of NBTXR3, and contribute to enrollment in five future global registrational studies across several tumor types and therapeutic combinations including immunotherapy Supports the expansion of global phase III registrational study in head and neck cancer into Greater China, with longer term strategic alignment across multiple tumor indications and therapeutic combinations PARIS & CAMBRIDGE, Mass. & SHANGHAI & PRINCETON, N.J. (BUSINESS WIRE) $NBTX#LianBio Regulatory News: NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a partnershi

New yorkUnited statesHong kongFrance generalUnited kingdomSouth koreaBrandon owensKate mcneilKonstantin poukalovDebra yuPorter novelliPierre louis germainElizabeth andersonCommunications investor relationsExchange commission onFrench financial markets authority autorit